Enfermedad arterial periférica

  1. Lozano Sánchez, F.S. 1
  2. Carnicero Martínez, J.A. 1
  3. Rubio Taboada, C. 1
  4. Valverde García, S. 1
  1. 1 Servicio de Angiología y Cirugía Vascular, Hospital Universitario de Salamanca, Departamento de Cirugía, Universidad de Salamanca, Salamanca, España
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades cardiovasculares (V)

Series: 13

Issue: 39

Pages: 2230-2242

Type: Article


More publications in: Medicine: Programa de Formación Médica Continuada Acreditado


Peripheral arterial disease (PAD) is a very common entity. Its frequent coexistence with other cardiovascular diseases affects its management and prognosis. PAD of the lower extremities is caused by progressive stenosis-obstruction of the arteries. Atherosclerosis is the most frequent cause, and is associated with cardiovascular risk factors (smoking, diabetes mellitus, etc.). The clinical manifestations vary according to the intensity of the blood deficit. The Fontaine (and Rutherford) classifications differentiate progression of the disease into asymptomatic, intermittent claudication, pain at rest and trophic lesions. Medical history (Edinburgh questionnaire), physical examination (palpation of pulses) and ankle/arm index (with/without stress test) enable diagnosis, classification, and indication of medical treatment. Arteriography or computed tomography (CT) is reserved for planning surgical treatment. Medical treatment includes risk factor control, exercise therapy and various drugs. Revascularisation techniques (open and/or endovascular) are indicated in very disabling claudication and critical ischaemia (pain at rest and/or minor trophic lesions). In inoperable cases, cell therapy may be considered. In advanced cases (gangrene) primary amputation is the only option.

Bibliographic References

  • Olinic DM, Spinu M, Olinic M, Homorodean C, Tataru DA, Liew A. Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. Int Angiol. 2018;37(4):327-34.
  • Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T. Editor’s Choice – 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Disease, in collabo-ration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305-68.3.
  • Lozano F, Rubio C. ¿Quién describió la claudicación intermitente? Sir Benjamin Collins Brodie. Angiologia. 2020;72(3):169-71.
  • Lozano Sánchez FS. Isquemia arterial crónica de las extremidades. Capítulo VI. En: Lozano F, ed. Cuadernos de patología vascular. Vol 2. Arterias. Madrid: Arán ed; 2005.
  • Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020-e30.
  • Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDer-mott MM. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-40.
  • Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14(3):156-70.
  • Conte MS. Enfermedad oclusiva arterial de la extremidad inferior: epide-miología e historia natural. En: Sidawy AN, Perler BA, editors. Rutherford. Cirugía vascular y terapia endovascular. 9ª ed. Medellin: AMOLCA ed; 2020. p. 54-62.
  • Jelani QU, Petrov M, Martínez SC, Holmvang L, Al-Shaibi K, Alasnag M. peripheral arterial disease in women: an overview of risk factor profile, clinical features, and outcomes. Curr Atheroscler Rep. 2018;20(8):40.
  • Lozano Sánchez FS, March García JR. Epidemiología de las enfermeda-des vasculares (Patología arterial). Datos españoles. En: Ibáñez Esquembre V, ed. Libro Blanco SEACV. La angiología y cirugía vascular en España. Madrid: Drug Farma; 2011. p. 13-32.
  • Lozano FS, Marinello J, Moreno RM, Aguilar MD, López Quintana A, González-Porras JR. Monitoring the practice of vascular surgery: findings from a national registry (1996-2011). World J Surg. 2014; 38(1):241-51.
  • Suárez C, Cairols M, Castillo J, Esmatjes E, Sala J, Llobet X, Palma JC; en representación de los investigadores del registro REACH España. Risk factor control and treatment of atherothrombosis. Spain REACH Registry Med Clin (Barc). 2007;129(12):446-50.
  • Blanes JI, Cairols MA, Marrugat J; ESTIME. Prevalence of peripheral artery disease and its associated risk factors in Spain: The ESTIME Stu-dy. Int Angiol. 2009;28(1):20-5
  • Alzamora MT, Forés R, Pera G, Baena Díez JM, Heras A, Sorribes M. Incidence of peripheral arterial disease in the ARTPER population cohort after 5 years of follow-up. BMC Cardiovasc Disord. 2016;16:8.
  • Lozano FS, González Porras JR, March JR, Carrasco E, Lobos JM; VITAL investigators. Differences between women and men with intermittent claudication: a crosssectional study. J Womens Health (Larchmt). 2014;23(10):834-41.
  • Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67.
  • Gerhard Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Cir-culation. 2017 21;135(12):e726-e79.
  • Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R. GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1-S109.e33.
  • Bellmunt S, Camafort M, Díaz S, Mancera J, Carrasco E, Lobos JM. Documento de consenso multidisciplinar en torno a la enfermedad arterial periférica. 1.ª ed. Madrid: Luzán 5, SA; 2012.
  • Lozano FS, González Porras JR, March JR, Lobos JM, Carrasco E, Ros E. Diabetes mellitus and intermittent claudication: a crosssectional study of 920 claudicants. Diabetol Metab Syndr. 2014;6(1):21.
  • Firnhaber JM, Powell CS. Lower extremity peripheral artery disease: diagnosis and treatment. Am Fam Physician. 2019;99(6):362-9.
  • Blanco Antona F, González Sarmiento R, García Cenador B, Lozano FS. Transdermal buprenorphine for controlling pain in patients with critical lower limb ischemia. Pain Med. 2020;21(5):1083-5.
  • Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45(10):1101-9.
  • Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517-38.
  • Simons JP, Robinson WP, Schanzer A. Enfermedad arterial de la extremidad inferior: manejo médico y toma de decisiones. En: Sidawy AN, Perler BA, editors. Rutherford. Cirugía vascular y terapia endovascular. 9ª ed. Medellin: AMOLCA ed. 2020. p. 63-82.
  • Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral arterydisease: A systematic review. Atherosclerosis. 2020;293:94-100.
  • Feringa HH, Bax JJ, Hoeks S, van Waning VH, Elhendy A, Karagiannis S. prognostic risk index for longterm mortality in patients with peripheral arterial disease. Arch Intern Med. 2007;167(22):2482-9.
  • Tóth Vajna Z, Tóth Vajna G, Gombos Z, Szilágyi B, Járai Z, Berczeli M. Screening of peripheral arterial disease in primary health care. Vasc Health Risk Manag. 2019;15:355-63.
  • Díaz Sánchez S, Piquer Farrés N, Fuentes Camps E, Bellmunt Montoya S, Sánchez Navárez I, Fernández Quesada F. Criterios de derivación entre niveles asistenciales de pacientes con enfermedad vascular. Documento de consenso SEMFYC-SEACV. Aten Primaria. 2012;44(9):556-61.
  • Lozano FS, March JR, González Porras JR, Carrasco E, Lobos JM, Ros E. Relative value of the Ankle-Brachial Index of intermittent claudication. Int J Clin Pract. 2014;68(12):1478-82.
  • Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C. American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-rachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890-909.
  • Lozano FS, March JR, González Porras JR, Carrasco E, Lobos JM, Areitio Aurtena A. Validation of the Walking Impairment Questionnaire for Spanish patients. Vasa. 2013;42(5):350-6.
  • Cea Soriano L, Fowkes FGR, Johansson S, Allum AM, García Rodríguez LA. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open. 2018;8(1):e018184.
  • Rodrigues E, Silva I. Supervised exercise therapy in intermittent claudication: a systematic review of clinical impact and limitations. Int Angiol. 2020;39(1):60-75.
  • Haga M, Hoshina K, Koyama H, Miyata T, Ikegami Y, Murai A. Bicycle exercise training improves ambulation in patients with peripheral artery disease. J Vasc Surg. 2020;71(3):979-87.
  • Bauersachs R, Wu O, Briere JB, Bowrin K, Borkowska K, Jakubowska A. Antithrombotic treatments in patients with chronic coronary artery disease or peripheral artery disease: a systematic review of randomised controlled trials. Cardiovasc Ther. 2020;2020:3057168.
  • Hernández JL, Lozano FS, Riambau V, Almendro Delia M, Cosín Sales J, Bellmunt Montoya S. Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. Drugs Context. 2020;9:2020-5-5.
  • McClure GR, Kaplovitch E, Narula S, Bhagirath VC, Anand SS. Rivaroxaban and aspirin in peripheral vascular disease: a review of implementation strategies and management of common clinical scenarios. Curr Cardiol Rep. 2019;21(10):115.
  • Cañizo MC, Lozano F, González Porras JR, Barros M, López Holgado N, Briz E. Peripheral endothelial progenitor cells (CD133 +) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy. 2007;9(1):99-102.
  • Martín Rufino JD, Lozano FS, Redondo AM, Villaron EM, Rueda R, Fernández Samos R. Sequential intravenous allogeneic mesenchy-mal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease). Stem Cell Res Ther. 2018;9(1):150.